Serina Therapeutics, Inc., formerly AgeX Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of wholly owned drug product candidates to treat neurological diseases and pain. Its POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. Its POZ Platform partners are at the forefront in advancing LNP delivery technology to develop RNA therapeutics. The Company is focused on the advancement of its lead drug candidate, SER-252 (POZ-apomorphine), for the treatment of advanced Parkinsonâs Disease through pre-clinical studies. The Company intends to advance SER 252 into Phase I clinical trials.
Number of employees: 7
SERINA THERAPEUTICS, INC. 
